- Home
- AENT vs SLS Comparison
AENT vs SLS Comparison
Compare AENT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- SLS
- Stock Information
- Founded
- AENT 1990
- SLS 2012
- Country
- AENT United States
- SLS United States
- Employees
- AENT N/A
- SLS N/A
- Industry
- AENT Durable Goods
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- SLS Health Care
- Exchange
- AENT Nasdaq
- SLS Nasdaq
- Market Cap
- AENT 161.5M
- SLS 169.6M
- IPO Year
- AENT N/A
- SLS N/A
- Fundamental
- Price
- AENT $5.56
- SLS $1.90
- Analyst Decision
- AENT Strong Buy
- SLS
- Analyst Count
- AENT 1
- SLS 0
- Target Price
- AENT $10.00
- SLS N/A
- AVG Volume (30 Days)
- AENT 46.7K
- SLS 3.6M
- Earning Date
- AENT 05-15-2025
- SLS 08-12-2025
- Dividend Yield
- AENT N/A
- SLS N/A
- EPS Growth
- AENT N/A
- SLS N/A
- EPS
- AENT 0.23
- SLS N/A
- Revenue
- AENT $1,072,641,000.00
- SLS N/A
- Revenue This Year
- AENT $4.77
- SLS N/A
- Revenue Next Year
- AENT N/A
- SLS N/A
- P/E Ratio
- AENT $25.32
- SLS N/A
- Revenue Growth
- AENT N/A
- SLS N/A
- 52 Week Low
- AENT $1.10
- SLS $0.77
- 52 Week High
- AENT $11.57
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- AENT 77.47
- SLS 59.56
- Support Level
- AENT $5.17
- SLS $1.98
- Resistance Level
- AENT $6.37
- SLS $2.27
- Average True Range (ATR)
- AENT 0.50
- SLS 0.16
- MACD
- AENT 0.23
- SLS 0.02
- Stochastic Oscillator
- AENT 75.89
- SLS 70.78
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.